In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rebate Card For Alcon’s Pataday Is More Than Meets The Eye, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.

You may also be interested in...

Nine Lives: Alcon’s Pataday Brochure Draws Yet Another FDA Letter

FDA’s most recent advertising letter to Alcon about its marketing practices makes the ninth such letter sent to the ophthalmology-focused firm in roughly 10 years; this time, the Office of Prescription Drug Promotion says the Novartis unit has omitted material facts and overstated efficacy and superiority in a brochure for Pataday.

‘Tis The Season… For An FDA Enforcement Letter To Alcon

The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.

After Three-Year Lull, Alcon Cited For Professional Ad Violations

DDMAC has sent five letters since 2003 for violations in promotional materials directed at health care professionals.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts